• KOR
  • ENG

ROPHIBIO

ROPHIBIO

Primary Menu

Skip to content
  • About
    • About ROPHIBIO
    • History
    • Executives
    • Organization
    • Location
  • Technology
    • Synthetic Promoter Technology
    • Genetically Engineered CHO Cell Technology
    • Cell Line Development and Cell Analysis Technologies
    • Stem Cell Therapy
  • Pipelines
    • Biotherapeutic Candidates
    • Biosimilar Drug Candidates
  • Notice
    • News
    • Contact us
  • Menu

Notice

Home > 뉴스/공지사항 > News

News

Total 1
Number Title Date Votes
1
Announcement for Stock Split and Share Transfer
| 2019.08.01 | Votes 0
2019.08.01 0
  • 1
Powered by KBoard

뉴스/공지사항

  • About ROPHIBIO
  • History
  • Executives
  • Organization
  • Location
  • Synthetic Promoter Technology
  • Genetically Engineered CHO Cell Technology
  • Cell Line Development and Cell Analysis Technologies
  • Stem Cell Therapy
  • Biotherapeutic Candidates
  • Biosimilar Drug Candidates
  • News
  • Contact us
  • Menu
194-25 Osongsaengmyeong-1ro (SB Plaza 406), Osong-eup, Heungdeok-gu, Cheongju-si, Chungbuk-do, Republic of Korea 28160.
T: +82-43-239-0080 | F: +82-303-0956-0080 | Email: info@rophibio.com
Copyright Rophibio, All Rights Reserved.

Announcement of base date and shareholder list closure period setting.

In accordance with Article 354 of the Commercial Act and Article 19 of our company's Articles of Incorporation, voting rights are granted to the shareholders listed in the shareholder register as of February 2, 2023. We hereby announce the suspension of changes in the stockholders' register, such as stock transfer, registration of pledge, change and cancellation of trust property, and indication and cancellation of trust property from February 3, 2023 to February 4, 2023 to confirm the right shareholders.

January 18, 2023

#406 Cheongju SB Plaza, 194-25 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do

CEO of Ropibio Co., Ltd. Sung Ho Hahm

Transfer agent, Lee Myeong-ho, president of Korea Securities Depository